Long-term durability of radiofrequency ablation for Barrett's-related neoplasia

Current Opinion in Gastroenterology

Volumn 31, Issue 4, 2015, Pages 316-320

  Haidry, Rehan ^a   Lovat, Laurence ^b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Barrett's esophagus; Endoscopic resection; Esophageal cancer; Radiofrequency ablation

Indexed keywords

ARTICLE; BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURVIVAL; ENDOSCOPIC SURGERY; ENDOSCOPIC THERAPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS DYSPLASIA; FOLLOW UP; GENETIC RISK; GOLD STANDARD; HIGH GRADE DYSPLASIA; HUMAN; INTESTINE METAPLASIA; INTRAMUCOSAL CARCINOMA; LONG TERM CARE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT COURSE THERAPY; ADENOCARCINOMA; CATHETER ABLATION; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; PRECANCEROUS CONDITIONS; PROCEDURES; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CATHETER ABLATION; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; HUMANS; NEOPLASM RECURRENCE, LOCAL; PRECANCEROUS CONDITIONS; TREATMENT OUTCOME;

EID: 84942590308     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000190     Document Type: Article

References (29)

1. Rice TW, Blackstone EH, Goldblum JR, et al. Superficial adenocarcinoma of the esophagus. J Thorac Cardiovasc Surg 2001;122:1077-1090.
2. Liu L, Hofstetter WL, Rashid A, et al. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol 2005;29:1079-1085.
3. Leers JM, De Meester SR, Oezcelik A, et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg 2011;253:271-278.
4. Fernando HC, Murthy SC, Hofstetter W, et al. The Society of Thoracic Surgeons practice guideline series: guidelines for the management of Barrett's esophagus with high-grade dysplasia. Ann Thorac Surg 2009;87:1993-2002.
5. Prasad GA, Wang KK, Buttar NS, et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology 2007;132:1226-1233.
6. Blazeby JM, Farndon JR, Donovan J, et al. A prospective longitudinal study examining the quality of life of patients with esophageal carcinoma. Cancer 2000;88:1781-1787.
7. Fitzgerald RC, Di PM, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014;63:7-42. Updated guidelines in the UK stipulating endoscopic therapy as first line for Barrett's esophagus neoplasia.
8. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011;140:1084-1091.
9. Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005;62:488-498.
10. Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 2007;66:460-468.
11. Dunkin B, Martinez J, Bejarano P, et al. Thin-layer ablation of human esophageal epithelium using a bipolar radiofrequency balloon device. Surg Endos 2006;20:125-130.
12. Roorda AK, Marcus SN, Triadafilopoulos G. Early experience with radiofrequency energy ablation therapy for Barrett's esophagus with and without dysplasia. Dis Esophagus 2007;20:516-522.
13. Sharma VK, Wang KK, Overholt BF, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 2007;65:185-195.
14. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy 2010;42:781-789.
15. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009;360:2277-2288.
16. Pouw RE, Gondrie JJ, Sondermeijer CM, et al. Eradication of Barrett esophagus with early neoplasia by radiofrequency ablation, with or without endoscopic resection. J Gastrointest Surg 2008;12:1627-1636.
17. Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy 2008;40:370-379.
18. Dunn JM, Banks MR, Oukrif D, et al. Radiofrequency ablation is effective for the treatment of high-grade dysplasia in Barrett's esophagus after failed photodynamic therapy. Endoscopy 2011;43:627-630.
19. Haidry RJ, Dunn JM, Butt MA, et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology 2013;145:87-95.
20. Haidry RJ, Butt MA, Dunn JM, et al. Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett's oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry. Gut 2014. Data showing improved outcomes over time in large cohort of patients.
21. Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology 2011;141:460-468.
22. Phoa KN, Pouw RE, Van Vilsteren FG, et al. Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology 2013;145:96-104.
23. Phoa KN, Pouw RE, Bisschops R, et al. Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II). Gut 2015. Follow-up data from EURO-II showing excellent short-term and long-term outcomes).
24. Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012;143:336-346.
25. Titi M, Overhiser A, Ulusarac O, et al. Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett's esophagus. Gastroenterology 2012;143:564-566.
26. Haidry RJ, Banks M, Gupta A, et al. PTU-041 Sub-squamous columnar neoplasia after successful radiofrequency ablation for Barrett's related neoplasia is rare but highlights requirement for long term follow up in these patients. Gut 2014;63(Suppl 1):A56.
27. Dixon MF. Gastrointestinal epithelial neoplasia: Vienna revisited. Gut 2002;51:130-131.
28. Small AJ, Sutherland SE, Hightower JS, et al. Comparative risk of recurrence of dysplasia and carcinoma after endoluminal eradication therapy of highgrade dysplasia versus intramucosal carcinoma in Barrett's esophagus. Gastrointest Endosc 2015. First high-volume data comparing IMC and HGD patients.
29. Haidry RJ, Banks M, Gupta A, et al. OC-014 Patients with intramucosal carcinoma arising in Barrett's eosophagus have similar outcomes to those with high grade dysplasia: data from the United Kingdom Registry. Gut 2014;63(Suppl 1):A7.